Luye Pharma’s Innovative Anti-Cancer Therapy Lurbinectedin to Benefit “Named Patients” in Hong Kong
HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) in Hong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medicine Pharma Services (AMPS), an international healthcare and pharmaceutical services company, the terms of which...
Ecolog International Appoints Juan Chaparro as Executive Director and Chairman of the Board
DUBAI, UAE, Jan. 9, 2023 /PRNewswire/ -- Ecolog International, a leading global provider of integrated services and logistics solutions for life support, supply chain, energy and healthcare industries, announced the appointment of Juan Chaparro as Executive Chairman of the Board, as of 01 January 2023. With over 30 years' experience as an executive in supply chain management, procurement and...
CGTN: China downgrades COVID-19 rules as nation readies for normal life
BEIJING, Jan. 9, 2023 /PRNewswire/ -- China put its downgraded COVID-19 measures into force on Sunday as the nation began to resume normal life after three years of strict pandemic management. The nation reopened its border ports for cargo transportation as well as inbound and outbound visitors. It also resumed services for Chinese citizens to apply...
China welcomes first arrivals following downgraded COVID management
BEIJING, Jan. 9, 2023 /PRNewswire/ -- A report from People's Daily: The first flights under China's new COVID-19 management for international travelers arrived at airports in south China's Guangdong province on Jan. 8, according to the national customs authority. Over 380 passengers were aboard two flights, CZ312 from Toronto to Guangzhou and ZH9024 from Singapore to Shenzhen, on the...
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
MELBOURNE, Australia, Jan. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco. As part of the Company's presentation (available to view or download from the investor page of the Telix...
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a highly selective small molecule Aurora...
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US. Fosun Pharma will have the...
Earable(R) Disrupts Sleep Tech with FRENZ(TM) Brainband Global Launch Event at CES 2023
LAS VEGAS, Jan. 7, 2023 /PRNewswire/ -- Earable® Neuroscience held a global launch event for its FRENZ™ Brainband at CES 2023. During the event, the company discussed innovations behind the award-winning device, potential to disrupt sleep tech, a special promotional price, and its 88 Pioneer project. Earable® Neuroscience, a deep tech company delivering scalable, human-centric solutions...
International Captive Exchange, A Health In Tech Company, Becomes Managing General Underwriter (MGU) for Liberty Mutual Insurance Company
STUART, Fla., Jan. 6, 2023 /PRNewswire/ -- International Captive Exchange, LLC (ICE), a Health In Tech, Inc. company, an industry-leading Insurtech company that delivers disruptive innovation and proprietary technology, has entered into an agreement to serve as the Managing General Underwriting for a program providing employer stop-loss insurance. Under the agreement, ICE will...
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD
Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced that an overview of Ocedurenone (KBP-5074) as a potential new treatment option addressing the unmet medical need...
